Arvinas, Inc. · NASDAQ:ARVN

Arvinas — Jefferies Global Healthcare Conference 2026

8 slides from Arvinas's conference presentation, Jun 2, 2026

  1. Slide 1: Jefferies Global Healthcare Conference

    Exhibit 99.1 -AARVI NAS Jefferies Global < Pp intare Conference Tuesday, June 2=> Thursday June 4, 2026 é Randy Teél, Ph.D.; President and Chief Executive Officer Noah Berkowitz, M.D., Ph.D., Chief Medical Officer

  2. Slide 2: Safe harbor and forward-looking statements

    Safe harbor and forward-looking statements ARVINAS ‘This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995that involve substantial risks and uncertainties, including statements regarding: the closing of the transaction with Ri

  3. Slide 3: A history of pioneering firsts

    . * ° . ° A history of pioneering firsts ARVINAS Arvinas creates first PROTAC First Phase 3 pivotal Aeviessfoundell degraders to cross crde data with PROTAC . blood-brain barrier grader partnership degrader as first PROTAC with Pfizer: $1B total protein degrader upfront, with $650m company non-dilut

  4. Slide 4: Translating vepdegestrant's promise into a treatment option for patients

    Translating vepdegestrant’s promise into a treatment option for . patients with ESR1 mutant, ER+/HER2- advanced breast cancer ARVINAS VEPPANU™ SON Entered into (vepdegestrant) ‘ i Licensing Agreement Received FDA | with Rigel Approval fee = Pharmaceuticals* (May 1, 2026) é 7 (May 11, 2026) Approval

  5. Slide 5: Leveraging the promise of our PROTAC platform to develop potentially transformational treatments

    Leveraging the promise of our PROTAC platform to develop potentially transformational treatments ARVINAS ARV-102 (LRRK2 degrader) * Potential to become the first disease-modifying therapy for PSP and other serious neurodegenerative diseases ARV-027 (polyQ-AR degrader) * Potential to become first dis

  6. Slide 6: Arvinas pipeline includes differentiated PROTAC degraders in neurology and oncology

    Arvinas pipeline includes differentiated PROTAC degraders in neurology and oncology PROGRAM INDICATION(S) PRECLINICA PHASE 1/1B PHASE 2 PHASE 3 ARV-102* PSP, Parkinson’s Planned initiation of Phase 1b/2 PSP trial in 2H 2026"" (LRRK2) Disease ARV-027* Spinal-Bulbar | (aan) Moser Atopy ARV-393* Non-Ho

  7. Slide 7: Multiple value-driving milestones anticipated ahead

    @oec. Multiple value-driving milestones anticipated ahead BRMINES Anticipated upcoming milestones: Neurology Anticipated upcoming milestones: Oncology ARV-102 ARV-027 ARV-393 ARV-6723 Oral LRRK2 degrader Oral polyQ-AR degrader Oral BCL6 degrader Oral HPK1 degrader 7 Share additional . Complete enrol

  8. Slide 8: Arvinas

    lanvinias ARVINAS

Arvinas — Jefferies Global Healthcare Conference 2026 on 6ix